85666-17-7
中文名稱
U-63557A
英文名稱
U-63557A
CAS
85666-17-7
分子式
C15H10NNaO3
分子量
275.23
MOL 文件
85666-17-7.mol
更新日期
2024/12/23 10:32:11
85666-17-7 結(jié)構(gòu)式
基本信息
中文別名
化合物 T11339化合物FUREGRELATE SODIUM
英文別名
U-63557Afuregralate sodium
SODIUM FUREGRELATE
FUREGRELATE SODIUM
FUREGRELATE SODIUM SALT
Furegrelate Sodium (U-63557A)
Sodium 5-(3-pyridinylmethyl)-2-benzofurancarboxylate
5-(3'-Pyridinylmethyl)benzofuran-2-carboxylate sodium
sodium:5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate
5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt
物理化學(xué)性質(zhì)
儲存條件−20°C
溶解度DMF: >25 mg/ml; DMSO: >21 mg/ml; Ethanol: >14.5 mg/ml; PBS pH 7.2: >16.5 mg/ml
形態(tài)白色至類白色結(jié)晶固體。
顏色White to light yellow
水溶解性Soluble in water at approximately 15mg/ml
U-63557A價格(試劑級)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-106080A | U-63557A Furegrelate sodium | 85666-17-7 | 5mg | 600元 |
2024/11/08 | HY-106080A | U-63557A Furegrelate sodium | 85666-17-7 | 10 mM * 1 mLin DMSO | 660元 |
2024/11/08 | HY-106080A | U-63557A Furegrelate sodium | 85666-17-7 | 10mg | 1000元 |
常見問題列表
生物活性
Furegrelate Sodium (U-63557A) 是一種有效的、口服的、選擇性的血栓素合酶 (thromboxane synthase) 抑制劑。Furegrelate Sodium 抑制人血小板微粒體血栓素 A2 (TxA2) 合酶,其 IC50 為 15 nM。Furegrelate Sodium 正在開發(fā)作為抗血小板藥物。體內(nèi)研究
Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery.
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation.
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.
Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.
Animal Model: | Mongrel dogs (19-30 kg) |
Dosage: | 1-5 mg/kg |
Administration: | Oral (via a gastric tube) |
Result: | Prevented blockage of the coronary artery. |